Dhyani Praveen, Sati Priyanka, Chand Attri Dharam, Sharma Eshita, Soni Ruchi, Sharifi-Rad Javad, Calina Daniela
Institute for Integrated Natural Sciences University of Koblenz Koblenz Germany.
Department of Biotechnology Kumaun University Bhimtal India.
Food Sci Nutr. 2025 Aug 4;13(8):e70744. doi: 10.1002/fsn3.70744. eCollection 2025 Aug.
The global rise in cancer incidence has driven the search for safer, more effective therapies, with natural compounds gaining increasing attention. Phloridzin, a dihydrochalcone glycoside abundant in apple trees ( spp.), has demonstrated notable anticancer properties. This review summarizes its pharmacological profile, natural sources, and structural characteristics, with a focus on its mechanisms of antitumor action. We conducted a structured literature search across SCOPUS, PubMed, Google Scholar, and TRIP databases, highlighting studies on phloridzin's anti-proliferative, pro-apoptotic, anti-inflammatory, and metabolic regulatory effects across various in vitro and in vivo cancer models. Key mechanisms include glucose transporter inhibition (GLUT1/2), modulation of PI3K/AKT/mTOR and JAK2/STAT3 signaling, and suppression of metastasis and angiogenesis. Despite compelling preclinical evidence, phloridzin's clinical application is limited by low bioavailability. Novel delivery systems and synthetic derivatives, such as fatty acid esters, have shown improved pharmacokinetic profiles and efficacy. Future studies should prioritize translational research and clinical trials to validate phloridzin's potential as an adjunct or alternative therapy in oncology.
全球癌症发病率的上升推动了对更安全、更有效治疗方法的探索,天然化合物越来越受到关注。根皮苷是一种在苹果树( spp.)中大量存在的二氢查耳酮糖苷,已显示出显著的抗癌特性。本综述总结了其药理特性、天然来源和结构特征,重点关注其抗肿瘤作用机制。我们在SCOPUS、PubMed、谷歌学术和TRIP数据库中进行了结构化文献检索,重点突出了在各种体外和体内癌症模型中关于根皮苷的抗增殖、促凋亡、抗炎和代谢调节作用的研究。关键机制包括葡萄糖转运蛋白抑制(GLUT1/2)、PI3K/AKT/mTOR和JAK2/STAT3信号通路的调节,以及转移和血管生成的抑制。尽管临床前证据令人信服,但根皮苷的临床应用受到低生物利用度的限制。新型给药系统和合成衍生物,如脂肪酸酯,已显示出改善的药代动力学特征和疗效。未来研究应优先进行转化研究和临床试验,以验证根皮苷作为肿瘤学辅助或替代疗法的潜力。
Cochrane Database Syst Rev. 2017-12-22
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2018-2-6
Mol Cancer. 2025-1-2
Front Biosci (Landmark Ed). 2024-11-27
Eur J Pharmacol. 2024-12-5
Cold Spring Harb Perspect Med. 2024-9-16
Int Immunopharmacol. 2024-5-30